Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: SAR445088 (IV), SAR445088 (SC); Drug
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Fairway, Kansas + 2 more

Conditions: Type 1 Diabetes
Interventions: ORMD-0801 Treatment A, ORMD-0801 Treatment B, Placebo; Drug · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tustin, California

Conditions: Presbyopia
Interventions: Clerio Vision LIRIC-modified Bifocal Contact Lens, Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens, Johnson & Johnson 1-Day Acuvue Moist Contact Lens, Clerio Vision Single Vision Contact Lens; Device
Lead sponsor: Clerio Vision, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Health Promotion
Interventions: Fun For Wellness (FFW); Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 48
States / cities: Bakersfield, California • La Jolla, California • La Palma, California + 42 more

Conditions: Healthy Adults
Interventions: EC5026 oral tablet, Placebo oral tablet; Drug · Other
Lead sponsor: EicOsis Human Health Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Stroke
Interventions: MR-001; Device
Lead sponsor: MedRhythms, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Healthy Participants
Interventions: AZD8630 (test formulation) via test inhaler, AZD8630 (reference formulation) via Monodose inhaler, Test inhaler, Monodose inhaler; Drug · Device
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Macular Edema
Interventions: Vamikibart, Ranibizumab, Sham Procedure; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Arcadia, California • Torrance, California • Walnut Creek, California + 7 more

Conditions: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Blinatumomab, Standard of Care Chemotherapy; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 12 more

Conditions: Aphasia, Apraxia of Speech, Stroke
Interventions: Sound Production Treatment - Blocked, Sound Production Treatment - Random; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Respiratory Depression
Interventions: Belbuca 300 µg, Belbuca 600 µg, Belbuca 900 µg, Oxycodone 30 mg, Oxycodone 60 mg, Placebo; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Amyotrophic Lateral Sclerosis, Healthy Volunteer
Interventions: SAR443820, Erythromycin ethyl succinate, Itraconazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy
Interventions: PF-05221304 Formulation A, PF-05221304 Formulation B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pancreatic Head Neoplasm, Delayed Gastric Emptying, Post Operative Ileus, Whipple Procedure
Interventions: pancreaticoduodenectomy; Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Macular Degeneration
Interventions: pazopanib eye drops, Ketoconozole tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Septic Shock
Interventions: Hydroxocobalamin, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Refractory Chronic Cough
Interventions: 3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI), Placebo (via DPI), 6 mg NOC-110 (via DPI), Placebo (via DPI) [2x Placebo capsules]; Drug
Lead sponsor: Nocion Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Phoenix, Arizona • Leesburg, Florida • Winter Park, Florida

Conditions: Medication Adherence, Acute Coronary Syndrome
Interventions: PST therapy; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: IgG4 Related Disease, IgG4-RD
Interventions: elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota

Conditions: Healthy Volunteers
Interventions: Decitabine-THU; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteers
Interventions: Treatment A, Treatment B, Treatment C, Treatment D, Treatment E; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
Interventions: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • Fort Myers, Florida • Tavares, Florida + 5 more

Conditions: Haemophilus Influenzae Type b
Interventions: GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™, Pediarix™, Prevnar 13™, Rotarix™, Engerix™-B, Infanrix™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 4,003 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 63
States / cities: Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more

Search by objective public record fields.

Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes

Bifocal Contact Lens Study for Adults With Age-Related Near Vision Loss

Fun For Wellness: Online Well-Being Promotion Intervention in a Patient Sample

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects

Outcomes and Health Economics of Stroke Using Rhythmic Auditory Stimulation

A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Treatments of Acquired Apraxia of Speech

Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS

Nasogastric Decompression Following Pancreaticoduodenectomy

Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops

A Trial of Vitamin B12 in Septic Shock

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Improving Medication Adherence in Post-ACS Patients

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People

A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants